May 25, 2021 -- Myriad Genetics is selling its Myriad RBM contract research services business to Q2 Solutions, a wholly owned subsidiary of Iqvia, for an undisclosed amount.
Myriad RBM specializes in contract research for the pharmaceutical industry and will be added to Q2 Solutions' testing, project management, supply chain, biorepository, biospecimen, and consent tracking solutions.
The divestiture of Myriad RBM will allow Myriad Genetics to accelerate its transformation plan and focus on the firm's core businesses in women's health, oncology, and mental health, Myriad said.
The agreement is subject to customary closing conditions and Myriad expects the transaction to close in the third quarter.
Copyright © 2021 scienceboard.net